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Background: Modifiable risk factors, including life-style habits and psychological variables, have been increasingly
demonstrated to have an important role in influencing morbidity and mortality in cardiovascular patients, and to
account for approximately 90% of the population risk for cardiac events.
Acceptance and Commitment Therapy (ACT) has shown effectiveness in promoting healthy behaviors, and
improving psychological well-being in patients with chronic physical conditions. Moreover, a first application of an
acceptance-based program in cardiac patients has revealed high treatment satisfaction and initial evidences of
effectiveness in increasing heart-healthy behaviour. However, no clinical trial to date has evaluated the efficacy of
an acceptance-based program for the modification of cardiovascular risk factors and the improvement of
psychological well-being, compared to usual secondary prevention care.
Methods: Approximately 168 patients will be recruited from an outpatient cardiac rehabilitation unit and randomly
assigned to receive usual care or usual care + a brief ACT-based intervention. The ACT group will be administered
five group therapy sessions integrating educational topics on heart-healthy behaviours with acceptance and
mindfulness skills. Participants will be assessed at baseline, six weeks later (post treatment for the ACT condition), at
six and twelve months follow-up.
A partially-nested design will be used to balance effects due to clustering of participants into small therapy groups.
Primary outcome measures will include biological indicators of cardiovascular risk and self-reported psychological
well-being. Treatment effects will be tested via multilevel modeling after which the mediational role of psychological
flexibility will be evaluated.
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Discussion: The ACTonHEART study is the first randomized clinical trial designed to evaluate the efficacy of a brief
group-administered, ACT-based program to promote health behavior change and psychological well-being among
cardiac patients. Results will address the effectiveness of a brief treatment created to simultaneously impact multiple
cardiovascular risk factors. Conducted in the context of clinical practice, this trial will potentially offer empirical
support to alternative interventions to improve quality of life and reduce mortality and morbidity rates among cardiac
patients.
Trial registration: clinicaltrials.gov/ (NCT01909102)
Keywords: Ischemic heart disease, Modifiable cardiovascular risk factors, Adherence, Psychological well-being, Quality
of life, Acceptance and Commitment Therapy, Behavior modification, Randomized clinical trialBackground
It has been demonstrated that modifiable risk factors play
an important and influential role in the morbidity and
mortality of cardiovascular patients [1-3] and account for
more than 90% of the population risk for acute myocardial
infarction (MI) [4]. A recent meta-analysis by Janssen and
colleagues [5], which analyzed 23 randomized trials of pri-
mary and secondary care programs developed from 1999-
2009, indicated that life-style modification programs may
improve risk factors and related life-style behaviors, and
reduce mortality, cardiac readmission, and non-fatal in-
farctions. However, research has shown poor long-term
adherence to recommended behaviors among cardiac pa-
tients even after the application of life-style intervention
programs [1,6-8]. Moreover, the majority of successful pro-
grams were both costly and labor intensive, utilizing nu-
merous sessions and lengthy intervention periods [5,9-13].
These time- and cost-consuming interventions reduce the
adoptability of the program to applied medical settings.
In the past, secondary prevention programs were al-
most exclusively focused on exercise. However, in order
to address the multiplicity of cardiovascular risk factors,
secondary prevention programs should provide inte-
grated behavioral care including exercise, health educa-
tion, lifestyle counseling, and psychological treatment to
address a wide range of modifiable risk factors such as
co-morbid presentations of both heart disease and de-
pression for example [14].
As such, it is important that other interventions are
developed and evaluated to address this shortcoming.
ACT [15], a “third wave” behavioral and cognitive ther-
apy, has a growing empirical base demonstrating its effi-
cacy for a wide range of conditions [16,17]. ACT has
been modified and empirically evaluated in several
chronic physical illnesses with varying treatment lengths
(3-hour workshop to 3-week retreats) [18]. ACT aims to
maximize psychological flexibility, which is the ability to
be fully present in each moment and to persist or
change behavior in the service of personal values [16].
Applications of acceptance-based interventions have
proven efficacious in fostering health behaviors, such asweight management [19,20], physical activity practice [21],
and smoking cessation [22]. This model has been success-
fully adapted to improve adherence to medical prescrip-
tions and adaptive functioning among patients with
chronic physical conditions, such as diabetes [23], epilepsy
[24,25], multiple sclerosis [26], chronic pain [27], and HIV
disease [28]. All of these ACT-based interventions had
short treatment durations, and were often administered in
a group setting. A large scale, randomized trial investigat-
ing the effectiveness of an acceptance-based intervention
to improve the health and quality of life among cardiac
patients has yet to be conducted. However, a pilot study
by Goodwin and colleagues [29] evaluated an application
of an acceptance-based program for cardiac patients and
provided initial evidence for effectively increasing heart-
healthy behaviours. Moreover, participants in this study
were highly satisfied with the intervention. In particular,
results showed large improvements in diet and moderate
increases in physical activity from pre- to post-treatment.
However, given the absence of a control group and the
small sample size of this initial investigation, large-scale
randomized clinical trials (RCT) are needed to test the ef-
ficacy of ACT-based interventions with cardiac patients.
Rationale for applying ACT to promote life-style changes
and adherence among cardiac patients
ACT is mainly focused on improving psychological flexi-
bility by fostering the ability to behave in a values-driven
manner. Traditional cognitive behavior therapy attempts
to dispute, change, and restructure the content of nega-
tive thoughts to reduce consequent psychological dis-
comfort. Rather than modifying the content of thoughts,
ACT attempts to change the relationship between the
person and his own thoughts and feelings [30]. In the
ACT model, experiential avoidance is defined as the at-
tempt to alter the form, frequency, or situational sensi-
tivity of difficult internal experiences such as thoughts,
emotions, and physical sensations often resulting in in-
creased distress [31]. Experiential avoidance may explain
the difficulty patients experience when faced with behav-
ior change despite knowledge of medical risks.
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tails distressing physical sensations, thoughts, and feelings;
thus individuals with a low ability to tolerate distress
might be less likely adopt and maintain behavioural
changes. For example, changes in diet often require com-
promises in portion-size and taste [32-34], exercise is as-
sociated with physical discomfort and exercise-anxiety
[21], and abstaining from nicotine is associated with crav-
ings [22,35]. Moreover, lower medication adherence has
been reported among HIV-positive patients avoiding dis-
tress [36]. Across domains, decreases in experiential
avoidance may increase adherence to health-behaviours.
Another ACT process useful in explaining behavior
change is the connection with key personal values, defined
as long-term desired qualities of living [16]. When an indi-
vidual loses contact with his life value, he may sacrifice
long-term behavioral goals and values (e.g., adopting a
healthy lifestyle) in the service of decreasing his very sali-
ent short-term goals (e.g., reducing present discomfort).
Short- and long-term distress tolerance is necessary to
adopt healthy (but strenuous) lifestyle changes.
Given ACT’s ability to address core theoretical pro-
cesses proposed to contribute to behavior change, ACT
appears to be particularly promising for increasing adher-
ence to low-risk lifestyles among cardiac patients (e.g., low
fat diet, smoking cessation, medication adherence)—a fun-
damental, but difficult goal to be attained.
Rationale for promoting psychological well-being among
cardiac patients using ACT
Given increasing evidence to suggest a causal association
between mood, stress, and the development and progno-
sis of coronary heart disease [37-39], the management of
psychological distress should represent an important
goal of secondary prevention programs.
In the last decade many studies on psychological flexi-
bility indicated an inverse association with a wide range
of psychological outcome measures (e.g., depression,
anxiety, job induced tension, worries, pain) and a posi-
tive association with quality of life, perceived health, and
positive emotional experiences with medium effect-sizes
[16,40-47]. Moreover, recent research on the ACT model
suggests that psychological flexibility mediates the ef-
fects of adaptive coping strategies on emotional and psy-
chological well-being [48,49].
Research to date supports the utility of ACT-based in-
terventions to modify health-behaviours and reduce psy-
chological distress. Thus, we propose that an ACT-based
intervention maybe useful for improving the physical
and psychological health of cardiac patients.
Study objectives and hypotheses
To the best of our knowledge this will be the first ran-
domized controlled trial to evaluate the efficacy of ACTin cardiac patients. Thus, the main aim of this research
is to examine the efficacy of a manualized ACT-group
therapy program for preventing the long-term deterior-
ation of several risk factors and lifestyle behaviors and
for improving psychological well-being and quality of life
in patients with IHD over a 12-months follow-up period.
In order to reflect Medical Research Council recom-
mended guidelines [50] as well as the multi-factorial na-
ture of the intervention, a number of primary outcome
measures will be considered.
Moreover, the study is aimed at exploring the mecha-
nisms of change surrounding the intervention with in-
creased psychological flexibility as a possible critical
mediator of intervention effects.
Specifically, the current study is designed to test the
following hypotheses:
Primary hypothesis: The proposed ACT intervention
will be associated with significantly better achievement,
compared to the usual care, in at least two of the follow-
ing primary outcome measures: LDL-cholesterol, resting
systolic blood pressure, body mass index, and psycho-
logical well-being measured by the Psychological Gen-
eral Well-Being (PGWB) Index.
As no RCT was available on ACT-based interventions
for cardiac patients, at the time of the study design we
were not able to predict the modification of these four
outcome variables as effect of the intervention.
Otherwise, expected levels of change on some of these
indicators can be projected for participants in the usual
care condition based on the GOSPEL study [51], a re-
cent Italian survey on a similar population. Results from
this study showed time-related worsening of the man-
agement of cardiac risk factors at 12-months follow-up.
In particular, in the usual care condition, the following
mean changes from baseline to 12-months follow-up
were observed: an increase of 0.4 mg/dl in LDL choles-
terol levels, an increase of 0.4 Kg/m2 in BMI and a
15.2% decrease in the rate of patients at target for rest-
ing systolic blood pressure [51].
We hypothesize that participants in the usual care
group will show mean changes in the aforementioned
variables comparable to those founded in the GOSPEL
study, while patients in ACT condition will achieve bet-
ter results on these primary outcomes with a medium
between-group effect size (a standardized mean differ-
ence between mean changes of at least 0.3 standard de-
viations is expected).
Secondary hypotheses: The intervention will also im-
prove a number of secondary outcomes: 1. adherence to
a heart-healthy lifestyle (increased physical activity; im-
proved dietary patterns, smoking status, medication ad-
herence); 2. perceived health-related quality of life; 3.
other biological indicators of cardiovascular risk (exer-
cise capability during an incremental bicycle stress test,
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to hip ratio).
Mediation hypotheses: The intervention will improve
levels of psychological flexibility and the change in this




This is a prospective randomized controlled clinical trial.
It is a two-arm, partially nested design with three follow-
up assessments (at the end of the treatment period, 6
and 12 months). Participants in the ACTonHEART con-
dition will be provided usual care plus an ACT-based
group program while those in the control condition will
receive standard usual medical care. Indeed, according
to the Medical Research Council guidelines [50] the
‘usual treatment’ may be more appropriate than a pla-
cebo condition in the case of trials evaluating complex
interventions.
The study protocol was approved by The Istituto
Auxologico Ethics Committee (2007000303).
Usual general practice care
Participants in both conditions will receive a standard-
ized outpatient CR program designed in accordance to
the best EU practice [14]. The program is individually
tailored and conducted by a multi-disciplinary team. The
CR physician is responsible for prescribing medication
according to guidelines. The program has an average
duration of 6-weeks and includes exercise training,
psycho-education, and behavioral counselling by the CR
team or a private practitioner. A letter will be sent to
family physicians recommending secondary prevention
goals. After the standard care period, patients will be
asked to report to the hospital to complete a 6-month
and 12-month assessment consisting of laboratory and
exercise tests. After each assessment, a copy of said re-
sults will be forwarded to the participant’s family phys-
ician, who will continue to provide on-going treatment
and medical advice as needed. In addition to standard
care, the ACTonHEART group will receive the ACT
intervention.
The ACTonHEART intervention
Participants randomly assigned to the ACTonHEART
condition will complete five 90-minutes sessions over
the course of 6-weeks based on ACT with the aim of
positively modifying health-related behaviors and im-
proving psychological health. The program will be devel-
oped on the basis of ACT-consistent protocols adapted
from a) Goodwin and colleagues’ Acceptance Based Be-
havior Therapy (ABBT) for cardiac patients [29] and b)
Acceptance-based treatment for the self-management ofdiabetes [23]. The program integrates educational topics
on heart healthy behaviours with mindfulness and ac-
ceptance training, address difficult thoughts and feelings,
clarification of health-related values, and behavioral
commitment. The intervention will be administered by
two interventionists (ACT therapist and doctoral-level
student) in treatment groups of 8 participants.
Sessions 1-4 of the intervention will be delivered
weekly, followed by a two week break between session 4
and 5. The content of each group-session will be struc-
turally flexible, and include both didactic and experien-
tial and metaphorical examples.
The sessions will be conducted at the cardiac rehabili-
tation gymnasium and each of them will last 90 minutes.
The ACTonHEART intervention will include the fol-
lowing four components:
Cardiac education, which consists of providing
information about recommended diet, exercise, and the
effects of risky behaviors such as smoking and poor
adherence to medication. Additionally, specific
behavioral techniques will be presented to address
some of the common barriers to adoption of a heart-
healthy lifestyle. Moreover, each session will include
group problem-solving to address barriers to meeting
individual behavioral goals.
Mindfulness, refers to engaging in one’s present
moment experience and adopting an open and curious
attitude instead of struggling with moment, even if the
moment is unpleasant [15,52]. Additionally,
mindfulness aims to increase self-awareness by noticing
all internal experiences (positive and negative) in the
moment. Previous control-based attempts to cope with
cardiovascular disease, such as avoidance of disease
cues, unpleasant thoughts and sensations, will be
explored to demonstrate the ineffectiveness of control
when pursuing a meaningful life. Participants will be
encouraged to defuse from thoughts and feelings by
turning attention toward the ‘noticing-self ’ (termed
defusion) instead of becoming attached to thoughts and
maneuvering through life on ‘auto-pilot’.
Acceptance and willingness, involves the active
awareness and embrace of difficult private internal
experiences without unnecessary attempts to control or
avoid unpleasant emotions. Acceptance is an alternative
to experiential avoidance. Participants will be taught to
increase adherence to a heart-healthy lifestyle by
increasing willingness to experience distressing
sensations and urges moment to moment (i.e., acceptance)
while engaging in health behaviors. By encouraging
participants to live in accordance with their values,
participants can engage in meaningful/pleasurable
activities despite experiencing unwanted emotions/
sensations.
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participant values and related behavioural goals will
increase engagement in values-driven behavior, or
committed action. Potential barriers to adopting value-
driven behaviours and maintaining committed action in
the long-term will be explored and addressed through
metaphors and experiential techniques.Participants, setting, and assignment
All participants referred to the outpatient CR unit at
S. Luca Hospital, Istituto Auxologico Italiano, Italy, will
be invited to participate in the study. Patients who wish
to participate will be screened for inclusion and exclu-
sion criteria.
Patients who will meet the following inclusion criteria
will be eligible for the study:
a) A definite diagnosis of IHD including recent (< 8
weeks) acute MI, acute coronary syndrome, surgical
revascularization (Coronary Artery By-pass Surgery)
b) Major modifiable cardiovascular risk factors assessed
using the INTERHEART Modifiable Risk Score [53];
higher scores indicate greater risk. Only subjects
with a full score > 9 will be included in the study
c) Age between 18 and 70 years
d) Fluency in spoken and written Italian language
e) Expression of written informed consent
Exclusion criteria for the study are: a) severe psychi-
atric disorders according to DSM-IV TR criteria [54] b)
mental incapacity to participate in the programme (e.g.
cognitive impairment).Assessment procedure
Participants will be asked to complete all study measures
before randomization. Follow-up repeated measures as-
sessment will be completed on all study participants six
weeks later (post treatment), and at 6- and 12-month
follow-up.
Demographic data such as gender, age, marital status,
level of education, and employment status will be assessed
in order to control for these potential confounders.
Medical data such as recurrence of cardiac events and
additional diagnoses (e.g. diabetes) that may confound
results will be retrieved from clinical records. Further-
more, a listing of participants’ current medications and
dosages at each time point will be used to assess the de-
gree to which the intervention is affecting change above
and beyond medication effects.
Participants in both groups will provide a history of
any psychological treatment or counselling to assess po-
tential familiarity with mindfulness- and acceptance-
based therapies.A range of physiological and psychological outcome
measures will assess the following: modifiable cardiovas-
cular risk factors, adherence to medication and recom-
mended life-style, and psychological well-being and
quality of life.
Adjusted change scores for all the outcome measures
will be calculated in order to assess the interventions
ability to produce changes over time.
Biological indicators of risk
Laboratory analysis will include fasting total cholesterol
(mg/dl), HDL and LDL cholesterol (mg/dl), triglycerides
(mg/dl), and glycosylated haemoglobin (%). Each blood
sample will be analyzed by a certified laboratory.
Resting blood pressure will be assessed via an aneroid
sphygmomanometer. Exercise capability will be consid-
ered the maximal power (Watts) reached during an in-
cremental bicycle stress test. Moreover, an additional
index of oxygen consumption, the double product, will
be calculated as a heart rate x systolic blood pressure
product.
Psychological well-being
Psychological health will be measured by the Psychological
General Well-Being Index [55], validated in Italian [56].
The PGWB is a self-administered questionnaire composed
by six sub-scales: anxiety, depression, positive well-being,
self-control, general health and vitality. Higher scores indi-
cate better health.
Quality of life
Health-related quality of life will be assessed by the SF36
questionnaire [57]. It is a widely used self-report instru-
ment validated in Italian [58], which is composed by
eight sub-scales: physical function, physical role, general
health, social function, experience of pain, mental health,
and emotional role and vitality. Physical component
summary (PCS) and mental component summary (MCS)
measures [59] will be used inlieu of the eight dimensions
of the SF-36 to reduce the number of statistical compari-
sons and type 2 error. Higher scores indicate better quality
of life.
Dietary habits
The Mediterranean diet has received support for the pri-
mary prevention of acute coronary syndrome [60,61]. Re-
sults from the CARDIO2000 study [62] showed an inverse
association of such dietary pattern with serum lipids,
blood pressures, inflammation, and coagulation markers
related to cardiovascular disease. Moreover, individuals
with higher scores of adherence to the Mediterranean diet
were less likely to have acute coronary syndrome [60].
Since several studies have suggested that dietary patterns
are more predictive of disease risk and mortality than
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sessment will be assessed through the Mediterranean Diet
Score [62], based on inherent characteristics of the Medi-
terranean diet. Questions focus on the frequency of usual
consumption of 11 main components of the Mediterra-
nean diet and each item is scored on an ordinal scale from
0 to 5. Scores are summed to obtain a total score ranging
from 0 to 55.
Exercise
Participants’ physical activity levels will be measured by
The International Physical Activity Questionnaire (IPAQ)
[65], a self-report questionnaire that assesses the number
of days per week and the number of times per day an indi-
vidual spends doing specific activities. The questionnaire
consists of 5 categories: job-related physical activity, trans-
portation physical activity, housework, household tasks in-
cluding family-care, recreation, sport and leisure time, and
time spent sitting. In order for an activity to be reported, a
minimum of 10 continuous minutes must be spent doing
the activity.
Smoking status
Self-reports of smoking status were collected from par-
ticipants at the end of treatment and at 6- and 12-
months follow-up. The actual smokers will be also asked
to report the average number of cigarettes smoked per
day. The 7-day point prevalence abstinence rate at each
assessment point will be used to assess the change of
smoking status over time.
Adherence to medication
Adherence to pharmacological treatment will be mea-
sured by the Morisky Medical Adherence scale-8 items
(MMAS) [66] that was developed from a previously vali-
dated four item scale [67] and supplemented with add-
itional items addressing 1) the factors that may affect
adherence 2) the circumstances surrounding adherence
behavior and 3) problems with the complexity of the
medical regimen The MMAS has a dichotomous re-
sponse category for each item and a 5-point Likert re-
sponse for the last item (“How often do you have
difficulty remembering to take all your medication?”).
Higher scores indicate lower adherence. The measure
has proven to be reliable (α = 0.83) and has shown good
concurrent and predictive validity [66]. The Italian ver-
sion of the scale has been recently validated [68].
Psychological inflexibility
Psychological inflexibility will be measured through the
Acceptance and Action Questionnaire-II [69]. The Italian
version of the questionnaire has shown good reliability
(α = 0.83) and high convergent validity [70]. Furthermore,
disease-specific psychological inflexibility will be measuredusing the Cardiovascular Disease Acceptance and Action
Questionnaire (CVD-AAQ), created for the proposed in-
vestigation. The CVD-AAQ was created by refocusing
items from the AAQ-II [69] toward cardiovascular disease.
The CVD-AAQ measures acceptance of thoughts and
feelings related to cardio-vascular illness and the degree to
which they interfere with valued action. It consists of 7
Likert-type items and showed good reliability in a prelim-
inary study with 258 cardiac patients. Correlations with
the AAQ-II [69] provide preliminary support for the con-
vergent validity of the CVD-AAQ. Moreover, CVD-
specific in flexibility is inversely associated with measures
of psychological well-being and medication adherence.
Sample size
The primary outcome variables of this study are the mean
changes on the following indicators: LDL-cholesterol, rest-
ing systolic blood pressure, body mass index, and psycho-
logical well-being measured by the PGW.
As outlined above, at the time of the study’s design, we
were unable to project the level of improvement on
these outcome measures as effect of the ACT interven-
tion over a 12 months follow-up period, since no data
on cardiac patients were available.
Hypothesizing a medium effect size of the ACT inter-
vention (in particular a standardized effect of at least 0.3
standard deviations) the following between-group differ-
ences on mean changes from baseline to 12-month
follow-up are expected: 8.8 mg/dl in LDL cholesterol,
4 mmHg on systolic resting blood pressure and 1.3 kg/m2
in BMI. According to general guidelines, a power level of
.80 is considered adequate to detect treatment effects [71].
In accordance with deJong and colleagues [72], a clustered
design will require 160 participants to detect medium
treatment effects with a statistical power of 0.8 and a sig-
nificance level of .05.
Assuming a drop-out rate of <5% (as found in the
GOSPEL study [51]), a sample size of 168 participants
was finally defined, resulting in 84 participants being
randomly assigned to each group.
Data on “lost to follow-up” participants will be ana-
lyzed to identify any relevant characteristics that may
differ from the remainder of the study group. All data
for the primary and secondary outcome measures will
be analyzed using an intention-to-treat analysis such that
participants will remain in their randomly assigned
groups at final analysis, regardless of actual participation
within such group.
Randomization procedure and blinding
After the baseline assessment, participants are random-
ized to either ACTonHEART or usual care with the con-
dition assignment determined via a computer generated
algorithm. A block randomization scheme is employed,
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diovascular risk factors assessed using the INTERHEART
Modifiable Risk Score (highest tertile vs. middle tertile).
Participants allocated to the ACT condition are then
scheduled into treatment groups. Randomization and
follow-up assessments will be administered by independ-
ent practitioners blind to condition assignment and re-
search hypotheses.
Statistical analysis
Preliminary analyses will be conducted to test paramet-
ric statistical assumptions. If strong violations are de-
tected, robust methods or data transformation will be
applied. Outcome measures will be examined with
intention-to treat analyses and analyses will be con-
ducted on treatment completers.
Since participants in the ACT condition will be clus-
tered into small therapy groups, the between-group vari-
ance should be taken into account. In fact, it has been
shown that ignoring this level of nesting in the data can
affect estimated variances and power to detect treatment
and covariate effects [73], significantly inflate the Type I
error rate and treatment effect size [74]. Thus, given the
partially-nested design of this study, data will be ana-
lysed according to the guidelines suggested by Daniel J.
Bauer and colleagues in their seminal paper [75]. Two-
tailed tests with an adjusted critical alpha of 0.01 (0.05/4)
will be conducted for examining the treatment effects on
the four primary outcomes. Furthermore, on the basis of
the best multilevel model structured in the primary ana-
lyses, the moderating effects of some putative covariates
such as gender, age, level of education, marital status, car-
diovascular disease status, and diabetes, will be explored
and no adjustment to alpha will be applied. Beyond these
analyses we also intend to explore the effects of ACT on
measures of dietary habits and physical activity, smoking
cessation, medication adherence and health-related quality
of life, exercise capability during an incremental bicycle
stress test, lipid profile, glycosylated haemoglobin level,
and waist to hip ratio. The mediating role of psychological
inflexibility will also be examined within the structured
multilevel model. The MLwiN 2.21 sofware (Centre for
Multilevel Modeling-CMM, University of Bristol) will be
used for data analysis.
Discussion
As shown by large epidemiological studies [76,77] car-
diovascular risk can be described as multi-factorial and
preventable because a greater percentage of the overall
risk is comprised of modifiable risk factors [1-3]. Un-
healthy life-styles, poor medication adherence, and psy-
chological distress affect the prognosis of cardiac
patients. ACT has proven efficacious at promoting and
maintaining life-style changes and improving quality oflife. Thus, it appears to be a promising method to im-
prove quality of life and disease progression.
However there is a paucity of research examining
treatment effects of ACT in the context of secondary
prevention of IHD. Conducted in a clinical context, the
ACTonHEART study will assess whether an ACT-based
intervention (compared to usual care) can improve psy-
chological health, and adherence to medical and behav-
ioral regimens among a sample of patients diagnosed
with IHD. ACTonHEART is developed in such a way
that multiple risk behaviors are targeted at once. Al-
though modification of each separate risk factor adds
considerably to the standard care of cardiovascular pa-
tients, the majority of these patients have more than one
risk factor. The compounded effects of multiple risk fac-
tors can be efficiently and effectively addressed with
comprehensive interventions.
The ACTonHEART study is innovative in a number of
ways. First, although ACT is becoming well-studied in
the traditional clinical context, large-scale application to
medical settings has not occurred. Second, the assess-
ment framework incorporates indicators of both physical
and psychosocial health. The inclusion of objective physi-
ological outcome measures constitutes an aspect of
innovation in ACT research. Last, the study will focus on
mediation mechanisms underlying treatment success and
presents possible links to systematic models on psycho-
logical flexibility, a key construct in ACT research.
Some aspects of the study design can limit recruitment
and retention of participants. For example, the inclusion
criterion of having an INTERHEART Modifiable Risk
Score > 9 may slow recruitment. However, it is believed
that floor effects and subsequent underestimation of
treatment effects can be reduced by targeting individuals
with adherence difficulties [78].
Among the major strengths of this study is the novelty
of utilizing ACT to modify multiple cardiac risk factors
with a brief intervention. This study is consistent with
the call for prevention and health promotion research
integrating psychosocial (e.g., depression) and behavioral
(e.g., physical activity) risk factors [79]. Moreover, the in-
clusion of an EU standardized-care condition will pro-
vide important information pertaining to the added
benefits of an ACT-based intervention and reduce infla-
tion of treatment effects.
Another methodological strength of the study is the
use of a multi-level model accounting for intraclass cor-
relation due to clustering of patients in small therapy
groups. Although several studies focuses on group therapy
interventions, very few take control for this additional
source of variance, potentially leading to significant bias.
This trial will be redacted following the CONSORT
guidelines for non-pharmacological trials [80], and out-
comes published in peer-reviewed clinical journals.
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To the best of the researcher’s knowledge, this study will
be the first randomized controlled trial to examine the
effectiveness of ACT to improve adherence to medical
and behavioral prescription among cardiac patients.
Conducted in the context of clinical practice, this trial will
potentially offer empirical support to alternative interven-
tions to improve quality of life and reduce mortality and
morbidity rates among cardiac patients. Moreover, by
virtue of its short duration, the program could potentially
be utilized for health promotion and the primary preven-
tion of CVD.
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